BioLife Solutions, Inc. (NASDAQ:BLFS) Shares Sold by Kornitzer Capital Management Inc. KS

Kornitzer Capital Management Inc. KS cut its stake in BioLife Solutions, Inc. (NASDAQ:BLFS) by 19.1% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 71,800 shares of the medical equipment provider’s stock after selling 17,000 shares during the period. Kornitzer Capital Management Inc. KS owned 0.16% of BioLife Solutions worth $1,167,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Nisa Investment Advisors LLC boosted its stake in BioLife Solutions by 167.2% in the 4th quarter. Nisa Investment Advisors LLC now owns 1,630 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 1,020 shares in the last quarter. Point72 Hong Kong Ltd purchased a new position in BioLife Solutions during the 1st quarter worth approximately $36,000. Cubist Systematic Strategies LLC purchased a new position in BioLife Solutions during the 1st quarter worth approximately $36,000. Lazard Asset Management LLC purchased a new position in BioLife Solutions during the 1st quarter worth approximately $45,000. Finally, Tower Research Capital LLC TRC raised its position in BioLife Solutions by 246.5% during the 3rd quarter. Tower Research Capital LLC TRC now owns 3,929 shares of the medical equipment provider’s stock worth $54,000 after buying an additional 2,795 shares during the last quarter. 93.24% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Sarah Aebersold sold 4,000 shares of BioLife Solutions stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $17.65, for a total transaction of $70,600.00. Following the completion of the transaction, the insider now directly owns 65,843 shares of the company’s stock, valued at approximately $1,162,128.95. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, insider Sarah Aebersold sold 4,000 shares of the business’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $17.65, for a total value of $70,600.00. Following the completion of the sale, the insider now owns 65,843 shares of the company’s stock, valued at approximately $1,162,128.95. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Amy Duross sold 6,135 shares of the business’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $16.86, for a total transaction of $103,436.10. Following the completion of the sale, the director now directly owns 34,508 shares of the company’s stock, valued at approximately $581,804.88. The disclosure for this sale can be found here. Insiders sold a total of 31,702 shares of company stock valued at $527,141 in the last three months. 2.70% of the stock is currently owned by corporate insiders.

BioLife Solutions Price Performance

NASDAQ:BLFS opened at $15.86 on Monday. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.86 and a quick ratio of 1.83. The firm has a market cap of $718.46 million, a price-to-earnings ratio of -10.43 and a beta of 1.67. The company has a 50 day moving average price of $17.44 and a 200-day moving average price of $15.36. BioLife Solutions, Inc. has a 1-year low of $8.92 and a 1-year high of $24.50.

BioLife Solutions (NASDAQ:BLFS) last posted its earnings results on Thursday, February 29th. The medical equipment provider reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.02. The firm had revenue of $32.73 million during the quarter, compared to analyst estimates of $32.70 million. BioLife Solutions had a negative net margin of 46.37% and a negative return on equity of 13.36%. Equities research analysts forecast that BioLife Solutions, Inc. will post -0.6 EPS for the current year.

Analyst Ratings Changes

Separately, Jefferies Financial Group started coverage on shares of BioLife Solutions in a research report on Thursday, April 4th. They set a “buy” rating and a $22.00 price target for the company. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $23.40.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.